Shopping Cart
- Remove All
- Your shopping cart is currently empty
Atrimustine, a conjugate of chlorambucil and β-estradiol benzoate, possesses antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $916 | 6-8 weeks | |
50 mg | $1,190 | 6-8 weeks | |
100 mg | $1,860 | 6-8 weeks |
Description | Atrimustine, a conjugate of chlorambucil and β-estradiol benzoate, possesses antitumor activity. |
In vitro | Atrimustine (Bestrabucil), a conjugate combining chlorambucil with β-estradiol benzoate, exhibits a high affinity for tumor cells, thereby boosting the antitumor efficacy of chlorambucil[1]. This compound demonstrates concentration-dependent inhibition of growth factor production in Shionogi carcinoma 115 (SC-115) cells, an androgen-responsive cancer cell line, across a range of 100 nM to 10 μM. This inhibition is evidenced through a 3H-thymidine uptake assay[2], highlighting Atrimustine's potential in hindering cancer cell proliferation. |
Alias | KM2210, Bestrabucil |
Molecular Weight | 720.72 |
Formula | C41H47Cl2NO6 |
Cas No. | 75219-46-4 |
Relative Density. | 1.1424 g/cm3 (Estimated) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.